Good stuff, thanks DD. So, presumably in the clinic at some point in 2016? I've been wanting to find a NASH play so may give ENTA consideration at some point. With the recent weakness, I see market cap down to ~$650M, which is much cheaper than ICPT and then you have the HCV business on top of course.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.